Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.

Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91

2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 2.71

Roll-in experience from the Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study. J Vasc Interv Radiol (2013) 1.52

Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient. J Am Coll Cardiol (2015) 1.40

Renovascular hypertension and ischemic nephropathy. Am J Hypertens (2010) 1.18

Renovascular hypertension: screening and modern management. Eur Heart J (2011) 1.13

Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. PLoS One (2013) 1.12

Atherosclerotic renal artery stenosis--diagnosis and treatment. Mayo Clin Proc (2011) 1.08

Management of hypertension in the elderly. Nat Rev Cardiol (2012) 0.98

Hypertension in chronic kidney disease: navigating the evidence. Int J Hypertens (2011) 0.95

2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. Catheter Cardiovasc Interv (2011) 0.94

Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep (2014) 0.92

Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging. BMC Cardiovasc Disord (2012) 0.90

Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89

Renal ostial angioplasty and stenting. Part 1: the routine procedure. Semin Intervent Radiol (2009) 0.86

Cardiovascular morbidity and mortality and renal artery stenosis. Prog Cardiovasc Dis (2009) 0.84

Atherosclerotic renovascular disease among hypertensive adults. J Vasc Surg (2009) 0.82

Update on intervention versus medical therapy for atherosclerotic renal artery stenosis. J Vasc Surg (2015) 0.80

Diagnosis and treatment of renal artery stenosis. Nat Rev Nephrol (2010) 0.80

Clinical outcomes in patients with renal artery stenosis treated with stent placement with embolic protection compared with those treated with stent alone. Vasc Endovascular Surg (2012) 0.80

Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol (2014) 0.80

Platelet activation in patients with atherosclerotic renal artery stenosis undergoing stent revascularization. Clin J Am Soc Nephrol (2011) 0.79

Experience of stenting for atherosclerotic renal artery stenosis in a cardiac catheterization laboratory: technical considerations and complications. Can J Cardiol (2009) 0.78

Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis. J Am Soc Hypertens (2015) 0.77

Pickering syndrome: high-risk stenting of a renal artery stenosis in a multimorbid patient presenting with progressive congestive heart failure. Clin Res Cardiol (2013) 0.76

Consequences of frequent hemodialysis: comparison to conventional hemodialysis and transplantation. Trans Am Clin Climatol Assoc (2011) 0.76

Successful percutaneous transluminal angioplasty for the treatment of renovascular hypertension with an atrophic kidney. Heart Vessels (2014) 0.75

Atherosclerotic renovascular hypertension : lessons from recent clinical studies. Electrolyte Blood Press (2010) 0.75

Use of renin-angiotensin system blockade in patients with renal artery stenosis. Clin J Am Soc Nephrol (2014) 0.75

Cardio classics revisited--focus on the role of candesartan. Vasc Health Risk Manag (2010) 0.75

Renal artery stenosis presenting with nephrotic-range proteinuria: a case report. Kidney Res Clin Pract (2015) 0.75

RX Herculink Elite(®) renal stent system: a review of its use for the treatment of renal artery stenosis. Med Devices (Auckl) (2012) 0.75

Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 14.49

A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg (2006) 10.79

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96

The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92

Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69

Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging (2005) 5.84

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77

One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20

Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation (2011) 4.95

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care (2006) 4.66

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58

Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27

Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA (2002) 3.88

Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77

Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med (2003) 3.54

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45

Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation (2005) 3.38

Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (2010) 3.16

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07

Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA (2010) 2.98

Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. J Am Coll Cardiol (2005) 2.87

Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project. Circulation (2013) 2.81

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72

Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation (2012) 2.71

Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation (2007) 2.63

Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62

Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care (2007) 2.62

A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56

Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol (2012) 2.56

Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA (2004) 2.55

C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes (2008) 2.50

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 2.49

Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem (2003) 2.49

Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci (2004) 2.47

Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43

The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes (2006) 2.40

Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem (2004) 2.40

The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. J Stroke Cerebrovasc Dis (2010) 2.35

The rationale and design of the AASK cohort study. J Am Soc Nephrol (2003) 2.34

Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32

The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg (2008) 2.29

Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA (2008) 2.28

Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26

Reduced renal function and sleep-disordered breathing in community-dwelling elderly men. Sleep Med (2008) 2.26

Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? Circulation (2010) 2.25

Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation (2003) 2.21

One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics (2007) 2.20

Does gum chewing ameliorate postoperative ileus? Results of a prospective, randomized, placebo-controlled trial. J Am Coll Surg (2006) 2.19

Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. J Am Coll Cardiol (2003) 2.18

Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol (2008) 2.12

Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09

Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation (2009) 2.09

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care (2010) 2.08

The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol (2006) 2.05

Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol (2007) 2.03

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (2012) 2.02

Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. Clin Cardiol (2015) 2.01

Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation (2008) 2.01

Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care (2009) 2.01

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J (2010) 2.00

Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation. Transplantation (2014) 2.00

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99

Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA (2003) 1.98

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA (2010) 1.97

Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97

Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94

An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91

Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.91

Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med (2005) 1.91

Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke (2002) 1.90

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90

Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89

[Coronary risk estimation in Spain using a calibrated Framingham function]. Rev Esp Cardiol (2003) 1.85

Vascular closure devices: the second decade. J Am Coll Cardiol (2007) 1.84

Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J (2014) 1.82